Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06242470 · ClinicalTrials.gov registry record · Phase 1
A Study of MGC026 in Participants With Advanced Solid Tumors
A Phase 1 study of Non-Small Cell Lung Cancer and Melanoma, sponsored by MacroGenics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 250
- Enrollment target
- 12
- Study locations
NCT06242470: Recruiting Phase 1 study of Non-Small Cell Lung Cancer and Melanoma, sponsored by MacroGenics.
NCT06242470 is a Phase 1 study of Non-Small Cell Lung Cancer and Melanoma that is actively recruiting participants, run by MacroGenics. The registered enrollment target is 250 participants, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (62% lower). The trial reports 12 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06242470, a Phase 1 study of Non-Small Cell Lung Cancer and Melanoma, is actively recruiting participants, sponsored by MacroGenics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 250 participants
- Enrollment target
- 12
- Study locations
Study Summary
The study is designed to understand the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of MGC026 in participants with relapsed or refractory, unresectable, locally advanced or metastatic solid tumors The study has a dose escalation portion and a cohort expansion portion of the study. Participants will receive MGC026 by intravenous (IV) infusion. The dose of MGC026 will be assigned at the time of enrollment. Participants may receive up to 35 treatments if there are no severe side effects and as long as the cancer does not get worse. Participants will be monitored for side effects, and progression of cancer, have blood samples collected for routing laboratory work, and blood samples collected for research purposes.
Conditions Studied
Interventions
- BIOLOGICAL MGC026 Dose Escalation
- BIOLOGICAL MGC026 Dose for Expansion
Study Locations (12)
Texas
- The University of Texas MD Anderson Cancer Center - Houston
- University of Texas Health Science Center at Houston - Houston
Other
- Oxford University Hospitals NHS Foundation Trust - Oxford
- The Royal Marsden NHS Foundation Trust - Sutton
California
- The Angeles Clinic and Research Institute - Los Angeles
Michigan
- START Midwest - Grand Rapids
New York
- START-New York Long Island - Lake Success
Oregon
- Providence Cancer Institute - Portland
Utah
- START Mountain Region - West Valley City
Queensland
- ICON Cancer Centre Wesley - Auchenflower
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2024-03-06 |
| Est. Completion | 2028-10 |
| Phase | Phase 1 |
What NCT06242470 shows while recruiting
NCT06242470 is an interventional study that assigns participants to a tested intervention. The registered 250 participants enrollment target is mid-sized for trials with a published cap, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (62% lower).
The record links to 10 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which MGC026 Dose Escalation is the first listed.
NCT06242470 lists 12 locations in 10 states (Texas, Other, California).
Frequently Asked Questions
What is clinical trial NCT06242470 about?
NCT06242470 is a clinical study titled "A Study of MGC026 in Participants With Advanced Solid Tumors". The study is designed to understand the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of MGC026 in participants with relapsed or refractory, unresectable, locally advanced or metastatic solid tumors The study has a dose escalation portion and a cohort exp...
What is the current status of trial NCT06242470?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 250 participants. The study started on 2024-03-06. Estimated completion is 2028-10.
What conditions does trial NCT06242470 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Melanoma, Advanced Solid Tumor, Endometrial Cancer, Bladder Cancer.
What interventions are being tested in trial NCT06242470?
The interventions under investigation include: MGC026 Dose Escalation (BIOLOGICAL), MGC026 Dose for Expansion (BIOLOGICAL).
Who is sponsoring clinical trial NCT06242470?
This trial is sponsored by MacroGenics, which has 36 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06242470 being conducted?
This trial has 12 study locations across California, Michigan, New York, Oregon, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06242470's enrollment target sits among peer trials
250 144th of 454 higher than 309 of 454 other Non-Small Cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-Small Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
RECRUITING · Phase 1
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00483249 · 250 participants · NA
Endovascular Exclusion of Thoracoabdominal and/or Paravisceral Abdominal Aortic Aneurysm
- NCT00777712 · 250 participants
Mechanisms Underlying Impaired Diabetic Wound Healing
- NCT01451502 · 250 participants · NA
Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units
- NCT01771718 · 250 participants
Pilot Study on In-vivo Non-invasive Skin Imaging Using Multiphoton Microscopy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI